Business
HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment
SANTA CLARA, Calif., December 10, 2025--HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment
About this update from Heartbeam, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/1d2b8fcfafe50219ec1000633abea199"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_.rCG.dH_D6_Kd4CA71SnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1d2b8fcfafe50219ec1000633abea199","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/uKOStqKq_RbGa_jZiaulNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/1d2b8fcfafe50219ec1000633abea199","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"FDA Clearance Granted After Successful Appeal, Overturning Prior Not Substantially Equivalent (NSE) Outcome","length":107,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"HeartBeam’s Credit-Card Sized Device Delivers Clinical-Grade Insights Directly to Patients Anytime, Anywhere","length":108,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Pivotal Milestone Unlocks Multiple Key Initiatives in Company’s Growth Strategy","length":79,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":294,"olType":false},{"type":"text","content":"SANTA CLARA, Calif., December 10, 2025--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company’s groundbreaking 12-lead electrocardiogram (ECG) synthesis software for the assessment of arrhythmias. This clearance follows HeartBeam’s successful appeal of a prior Not Substantially Equivalent (NSE) determination.","length":526,"tagName":"p","attribs":{}},{"type":"text","content":"Unlike any single-lead or 6-lead consumer device, HeartBeam’s patented cable-free technology captures the heart’s electrical signals in three non-coplanar dimensions and synthesizes them into a 12-lead ECG representation. This allows patients to obtain an ECG reading for their arrhythmia from the comfort of home, or wherever they happen to be, representing a new level of convenience and peace of mind. The syn...